MCID: PRG003
MIFTS: 37

Progesterone-Receptor Negative Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Progesterone-Receptor Negative Breast Cancer

MalaCards integrated aliases for Progesterone-Receptor Negative Breast Cancer:

Name: Progesterone-Receptor Negative Breast Cancer 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:0060078

Summaries for Progesterone-Receptor Negative Breast Cancer

MalaCards based summary : Progesterone-Receptor Negative Breast Cancer is related to breast cancer and scirrhous adenocarcinoma. An important gene associated with Progesterone-Receptor Negative Breast Cancer is PGR (Progesterone Receptor), and among its related pathways/superpathways are Gastric cancer and Proteoglycans in cancer. The drugs Bevacizumab and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, t cells and brain, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

Related Diseases for Progesterone-Receptor Negative Breast Cancer

Diseases in the Progesterone-Receptor Positive Breast Cancer family:

Progesterone-Receptor Negative Breast Cancer

Diseases related to Progesterone-Receptor Negative Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Related Disease Score Top Affiliating Genes
1 breast cancer 10.3
2 scirrhous adenocarcinoma 10.1 ERBB2 PGR
3 breast apocrine carcinoma 10.1 ERBB2 PGR
4 glassy cell carcinoma of the cervix 10.1 ERBB2 PGR
5 breast medullary carcinoma 10.1 ERBB2 PGR
6 progesterone-receptor positive breast cancer 10.1 ERBB2 PGR
7 apocrine adenocarcinoma 10.1 ERBB2 PGR
8 uterine body mixed cancer 10.1 ERBB2 PGR
9 breast benign neoplasm 10.1 ERBB2 PGR
10 thoracic benign neoplasm 10.1 ERBB2 PGR
11 uterine corpus cancer 10.1 ERBB2 PGR
12 mixed cell type cancer 10.1 ERBB2 PGR
13 breast secretory carcinoma 10.1 ERBB2 PGR
14 bilateral breast cancer 10.1 ERBB2 PGR
15 breast papillary carcinoma 10.1 ERBB2 PGR
16 papillary adenocarcinoma 10.1 ERBB2 PGR
17 triple-receptor negative breast cancer 10.1 ERBB2 PGR
18 fallopian tube carcinoma 10.1 ERBB2 PGR
19 estrogen-receptor negative breast cancer 10.1 ERBB2 PGR
20 sweat gland cancer 10.1 ERBB2 PGR
21 breast fibroadenoma 10.0 ERBB2 PGR
22 female breast cancer 10.0 ERBB2 PGR
23 malignant ovarian surface epithelial-stromal neoplasm 10.0 ERBB2 PGR
24 ovary epithelial cancer 10.0 ERBB2 PGR
25 breast carcinoma in situ 10.0 ERBB2 PGR
26 keratoconjunctivitis sicca 10.0 ERBB2 TLR4
27 sporadic breast cancer 10.0 ERBB2 PGR
28 papillary carcinoma 10.0 ERBB2 PGR
29 breast disease 9.9 ERBB2 PGR
30 peritoneal mesothelioma 9.9 EGFR PGR
31 prostatic hypertrophy 9.9 EGFR PGR
32 breast intraductal proliferative lesion 9.9 EGFR ERBB2
33 tumor suppressor gene on chromosome 11 9.8 EGFR ERBB2
34 acneiform dermatitis 9.8 EGFR ERBB2
35 adenosquamous cell lung carcinoma 9.8 EGFR ERBB2
36 hidradenocarcinoma 9.8 EGFR ERBB2
37 gallbladder adenocarcinoma 9.8 EGFR ERBB2
38 small intestinal adenocarcinoma 9.8 EGFR ERBB2
39 helicobacter pylori infection 9.8 EGFR TLR4
40 exanthem 9.8 EGFR ERBB2
41 cervical adenocarcinoma 9.7 EGFR ERBB2
42 salivary gland cancer 9.7 EGFR ERBB2
43 oral cavity cancer 9.7 EGFR ERBB2
44 mucoepidermoid carcinoma 9.7 EGFR ERBB2
45 breast adenocarcinoma 9.6 EGFR ERBB2
46 pancreatic ductal adenocarcinoma 9.6 EGFR ERBB2
47 atherosclerosis susceptibility 9.6 RETN TLR4
48 gastrointestinal system cancer 9.6 EGFR ERBB2
49 intracystic papillary adenoma 9.5 EGFR ERBB2 PGR
50 breast scirrhous carcinoma 9.5 EGFR ERBB2 PGR

Graphical network of the top 20 diseases related to Progesterone-Receptor Negative Breast Cancer:



Diseases related to Progesterone-Receptor Negative Breast Cancer

Symptoms & Phenotypes for Progesterone-Receptor Negative Breast Cancer

GenomeRNAi Phenotypes related to Progesterone-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.8 EGFR ERBB2
2 Decreased viability with paclitaxel GR00179-A-3 8.8 EGFR

MGI Mouse Phenotypes related to Progesterone-Receptor Negative Breast Cancer:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.56 TLR4 EGFR ERBB2 PGR
2 limbs/digits/tail MP:0005371 9.46 TLR4 EGFR ERBB2 PGR
3 muscle MP:0005369 9.26 TLR4 EGFR ERBB2 PGR
4 neoplasm MP:0002006 8.92 TLR4 EGFR ERBB2 PGR

Drugs & Therapeutics for Progesterone-Receptor Negative Breast Cancer

Drugs for Progesterone-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
3
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
4
Fluorouracil Approved Phase 3 51-21-8 3385
5
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1 57-83-0 5994
6
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
7
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
8
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
9
Goserelin Approved Phase 3 65807-02-5 5311128 47725
10
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
11
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
12
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
13
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
15
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
16
Docetaxel Approved May 1996, Investigational Phase 3 114977-28-5 148124 9877265
17
Doxil Approved June 1999 Phase 3,Phase 2 31703
18 Alkylating Agents Phase 3,Phase 2,Phase 1
19 Angiogenesis Inhibitors Phase 3,Phase 2
20 Angiogenesis Modulating Agents Phase 3,Phase 2
21 Anti-Bacterial Agents Phase 3,Phase 2
22 Antibiotics, Antitubercular Phase 3,Phase 2
23 Antimetabolites Phase 3,Phase 2
24 Antimetabolites, Antineoplastic Phase 3,Phase 2
25 Antirheumatic Agents Phase 3,Phase 2
26 Estrogens Phase 3,Phase 2,Phase 1
27 Hormone Antagonists Phase 3,Phase 2,Phase 1
28 Hormones Phase 3,Phase 2,Phase 1
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
30 Immunosuppressive Agents Phase 3,Phase 2
31 Progestins Phase 3,Phase 2,Phase 1
32 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
33 Albumin-Bound Paclitaxel Phase 2, Phase 3
34 Anti-Infective Agents Phase 2, Phase 3
35 Antimitotic Agents Phase 2, Phase 3, Phase 1
36 Antineoplastic Agents, Phytogenic Phase 2, Phase 3, Phase 1
37 Antiviral Agents Phase 2, Phase 3
38 Antineoplastic Agents, Hormonal Phase 3,Phase 2
39 Dermatologic Agents Phase 3,Phase 2
40 Folic Acid Antagonists Phase 3,Phase 2
41 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
42 Vitamin B Complex Phase 3,Phase 2
43 triamcinolone acetonide Phase 3
44 Triamcinolone diacetate Phase 3
45 Triamcinolone hexacetonide Phase 3
46 Folate Nutraceutical Phase 3,Phase 2
47 Vitamin B9 Nutraceutical Phase 3,Phase 2
48
Medroxyprogesterone acetate Approved, Investigational Phase 2 71-58-9
49
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
50
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953

Interventional clinical trials:

(show all 40)

# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
2 Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Completed NCT01881230 Phase 2, Phase 3 nab-Paclitaxel 125 mg/m2;Carboplatin AUC 2;gemcitabine 1000 mg
3 Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Completed NCT00427245 Phase 3 cyclophosphamide;goserelin acetate
4 S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Completed NCT00068601 Phase 3 cyclophosphamide;goserelin acetate
5 Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer Completed NCT00022516 Phase 3 Cyclophosphamide;Methotrexate
6 MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer Recruiting NCT01805076 Phase 3
7 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
8 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
9 S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Active, not recruiting NCT00070564 Phase 3 AC regimen;cyclophosphamide;doxorubicin hydrochloride;paclitaxel
10 Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer Completed NCT00577122 Phase 2 Medroxyprogesterone progesterone acetate (MPA);Medroxyprogesterone with Cyclophosphamide + Methotrexate
11 F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer Completed NCT00602043 Phase 2
12 Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery Completed NCT00559507 Phase 2 saracatinib
13 Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery Completed NCT00194779 Phase 2 doxorubicin hydrochloride;cyclophosphamide;paclitaxel;capecitabine;methotrexate;vinorelbine tartrate;tamoxifen citrate;letrozole
14 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed NCT00003199 Phase 2 tamoxifen citrate;busulfan;thiotepa;melphalan
15 Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer Completed NCT01105312 Phase 1, Phase 2 letrozole;panobinostat
16 S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer Completed NCT00856492 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
17 Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer Completed NCT00834678 Phase 1, Phase 2 bendamustine;erlotinib;Maintenance erlotinib
18 Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery Completed NCT00424203 Phase 2 AC regimen;cyclophosphamide;doxorubicin hydrochloride
19 Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer Recruiting NCT02315196 Phase 2 pegylated liposomal doxorubicin hydrochloride;epirubicin hydrochloride;carboplatin;paclitaxel
20 PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Recruiting NCT01037790 Phase 2 PD-0332991
21 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer Active, not recruiting NCT00733408 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation;erlotinib hydrochloride
22 Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer Active, not recruiting NCT01818063 Phase 2 Paclitaxel;Carboplatin;Doxorubicin;Cyclophosphamide;Veliparib
23 Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients Active, not recruiting NCT01372579 Phase 2 eribulin mesylate;carboplatin
24 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer Active, not recruiting NCT01463072 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
25 Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery Active, not recruiting NCT01147016 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
26 Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery Terminated NCT01234532 Phase 2 entinostat;anastrozole
27 Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer Terminated NCT01151449 Phase 2 gamma-secretase/Notch signalling pathway inhibitor RO4929097
28 A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer Withdrawn NCT00252811 Phase 2 Gefitinib
29 Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer Withdrawn NCT01100489 Phase 2
30 Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery Withdrawn NCT01612910 Phase 2 oral microencapsulated diindolylmethane
31 Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer Completed NCT00516243 Phase 1 defined green tea catechin extract
32 Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer Completed NCT01104259 Phase 1 veliparib;cisplatin;vinorelbine tartrate
33 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
34 Clinical Trial of Trametes Versicolor in Women With Breast Cancer Completed NCT00680667 Phase 1
35 Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32 Unknown status NCT01666171 metformin hydrochloride
36 Studying Biopsy Samples in Women Undergoing First-Line Chemotherapy for Metastatic Breast Cancer Completed NCT00870168 chemotherapy
37 Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer Completed NCT00755313 aromatase inhibition therapy;carboplatin;cyclophosphamide;docetaxel;doxorubicin hydrochloride
38 Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer Completed NCT00115505
39 Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases Completed NCT00072293
40 Assessment of Candidate Protein Expression in Breast Cancer Specimens Recruiting NCT00918892

Search NIH Clinical Center for Progesterone-Receptor Negative Breast Cancer

Genetic Tests for Progesterone-Receptor Negative Breast Cancer

Anatomical Context for Progesterone-Receptor Negative Breast Cancer

MalaCards organs/tissues related to Progesterone-Receptor Negative Breast Cancer:

38
Breast, T Cells, Brain, Lymph Node, Bone

Publications for Progesterone-Receptor Negative Breast Cancer

Articles related to Progesterone-Receptor Negative Breast Cancer:

(show all 11)
# Title Authors Year
1
Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. ( 28875243 )
2017
2
<i>SF3B1</i> mutation is a poor prognostic indicator in luminal B and progesterone receptor-negative breast cancer patients. ( 29383138 )
2017
3
Elevated Resistin Gene Expression in African American Estrogen and Progesterone Receptor Negative Breast Cancer. ( 27314854 )
2016
4
Mediation of Racial and Ethnic Disparities in Estrogen/Progesterone Receptor-Negative Breast Cancer by Socioeconomic Position and Reproductive Factors. ( 27076668 )
2016
5
Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer. ( 26392082 )
2015
6
Reproductive risk factors and oestrogen/progesterone receptor-negative breast cancer in the Breast Cancer Family Registry. ( 24548865 )
2014
7
A model of spontaneous mouse mammary tumor for human estrogen receptor- and progesterone receptor-negative breast cancer. ( 25230850 )
2014
8
Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women. ( 20647407 )
2010
9
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. ( 16145046 )
2005
10
Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. ( 15041725 )
2004
11
Induction of progesterone receptor in an estrogen, progesterone receptor-negative breast cancer cell line. ( 3702420 )
1986

Variations for Progesterone-Receptor Negative Breast Cancer

Expression for Progesterone-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Progesterone-Receptor Negative Breast Cancer.

Pathways for Progesterone-Receptor Negative Breast Cancer

Pathways related to Progesterone-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.3 EGFR ERBB2 PGR
2 11.74 EGFR ERBB2 TLR4
3
Show member pathways
11.5 EGFR ERBB2
4
Show member pathways
11.43 EGFR ERBB2 TLR4
5 11.39 EGFR ERBB2
6 11.37 EGFR ERBB2
7 11.33 EGFR ERBB2
8 11.29 EGFR ERBB2
9 11.18 EGFR ERBB2
10
Show member pathways
11.17 EGFR ERBB2 PGR
11 11.06 EGFR ERBB2
12 10.86 EGFR ERBB2
13 10.8 EGFR ERBB2
14 10.8 EGFR ERBB2 TLR4

GO Terms for Progesterone-Receptor Negative Breast Cancer

Cellular components related to Progesterone-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endosome membrane GO:0010008 9.13 EGFR ERBB2 TLR4
2 receptor complex GO:0043235 8.8 EGFR ERBB2 TLR4

Biological processes related to Progesterone-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol phosphorylation GO:0046854 9.56 EGFR ERBB2
2 wound healing GO:0042060 9.55 EGFR ERBB2
3 positive regulation of cell growth GO:0030307 9.54 EGFR ERBB2
4 cellular response to mechanical stimulus GO:0071260 9.52 EGFR TLR4
5 positive regulation of inflammatory response GO:0050729 9.51 EGFR TLR4
6 positive regulation of epithelial cell proliferation GO:0050679 9.49 EGFR ERBB2
7 positive regulation of MAP kinase activity GO:0043406 9.48 EGFR ERBB2
8 positive regulation of smooth muscle cell proliferation GO:0048661 9.46 EGFR RETN
9 cellular response to growth factor stimulus GO:0071363 9.43 EGFR ERBB2
10 signal transduction by protein phosphorylation GO:0023014 9.4 EGFR ERBB2
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.37 EGFR TLR4
12 cellular response to epidermal growth factor stimulus GO:0071364 9.32 EGFR ERBB2
13 ERBB2 signaling pathway GO:0038128 9.26 EGFR ERBB2
14 regulation of cell motility GO:2000145 9.16 EGFR ERBB2
15 regulation of ERK1 and ERK2 cascade GO:0070372 8.96 EGFR ERBB2
16 negative regulation of ERBB signaling pathway GO:1901185 8.62 EGFR ERBB2

Molecular functions related to Progesterone-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.54 EGFR ERBB2 TLR4
2 protein phosphatase binding GO:0019903 9.32 EGFR ERBB2
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.26 EGFR ERBB2
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.16 EGFR ERBB2
5 transmembrane signaling receptor activity GO:0004888 9.13 EGFR ERBB2 TLR4
6 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.62 EGFR ERBB2

Sources for Progesterone-Receptor Negative Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....